Yap J, Slade D, Goddard H, et al. - Researchers conducted a phase 2 double‐blind randomized control trial in order to compare the safety and efficacy of 10% sinecatechins (Veregen) ointment vs placebo in the treatment of usual type vulvar intraepithelial neoplasia (uVIN). They performed randomization of eligible patients to receive either sinecatechins or placebo ointment (applied three times daily for 16 weeks) and followed them up at 2, 4, 8, 16, 32 and 52 weeks. Although no difference was observed in histological response between the two treatment arms, 10% sinecatechins application is identified as safe and shows promise in inducing clinical resolution of uVIN lesions and symptom improvement, thus yielding support for further investigation in a larger multicentre study.